• Sanofi Pasteur Ltd., the vaccines division of Sanofi SA, of Paris, initiated a Phase III program called Cdiffense to evaluate the safety, immunogenicity and efficacy of its investigational vaccine to prevent primary symptomatic Clostridium difficile infection (CDI) in at-risk individuals. The Cdiffense program is recruiting volunteers at about 100 sites in the U.S. for a randomized, observer-blind, placebo-controlled, multicenter, multinational trial that will include up to 15,000 adults across 17 countries. The FDA granted fast-track designation to the investigational CDI vaccine in 2010.